Related by context. All words. (Click for frequent words.) 79 limiting toxicity 79 DLTs 71 tolerated dose MTD 71 hematologic toxicity 71 events SAEs 67 myelosuppression 66 toxicities 66 severe hypersensitivity reactions 66 GSK# [001] 66 dosing cohorts 66 hypercalcemia 66 teriflunomide 66 QTc prolongation 66 Bezielle 66 Toxicities 66 huC# DM4 66 preclinically 65 anti leukemic 65 antitumor activity 65 Ophena TM 65 lymphopenia 65 oral prodrug 65 laboratory abnormalities 65 hematological toxicities 65 HGS ETR1 65 nephrotoxicity 65 dosage regimens 65 elotuzumab 65 dose cohorts 65 pharmacokinetics PK 64 plasma pharmacokinetics 64 desvenlafaxine succinate 64 alvespimycin 64 dosing cohort 64 ascending doses 64 pharmacodynamic 64 clinically meaningful differences 64 pharmacodynamic PD 64 TEAEs 64 ascending dose 64 limiting toxicity DLT 64 hematological toxicity 64 cytogenetic response 64 mg/m2 dose 64 discontinuations 64 evaluable subjects 64 PRT# 64 favorable pharmacokinetic profile 64 secondary efficacy endpoints 64 cytopenias 64 thrombocytopenia 64 events AEs 64 FOLPI 64 hypomagnesemia 64 mGluR5 NAM 64 maximally tolerated dose 64 evaluable patients 64 docetaxel chemotherapy 64 MCyR 64 neutropenia dehydration dyspnea 64 PRX# 63 PREZISTA r 63 dose cohort 63 refractory NSCLC 63 febrile neutropenia 63 PSMA ADC 63 INCB# [001] 63 pharmacokinetic interactions 63 nab paclitaxel 63 Seliciclib 63 hematological adverse 63 CIMZIA ™ 63 velafermin 63 hematologic adverse 63 virologic breakthrough 63 refractory gout 63 Tarceva TM 63 SAEs 63 posaconazole 63 ALT elevations 63 Phase 2a trial 63 PEG SN# 63 hematologic toxicities 63 Panzem R NCD 63 patients evaluable 63 APTIVUS r 63 Traficet EN 63 MAGE A3 ASCI 63 dose escalation 63 systemically administered 63 heavily pretreated patients 63 pharmacokinetic PK 63 #mg/m# [001] 63 myeloproliferative diseases 62 relapsed MM 62 phase Ib 62 fosbretabulin 62 thromboembolic events 62 pharmacokinetic profile 62 Pharmacokinetics PK 62 evaluable 62 dexpramipexole 62 K ras mutations 62 tumor lysis syndrome 62 pertuzumab 62 8mg/kg 62 discontinuations due 62 haematologic 62 double blinded placebo 62 VP# [004] 62 QT QTc 62 PEG Interferon lambda 62 CANCIDAS 62 TACI Ig 62 administered subcutaneously 62 mg kg dose 62 cilengitide 62 Azedra 62 ISTODAX 62 cardiac toxicity 62 GAMMAGARD 62 coadministration 62 CA4P 62 INCB# [003] 62 neutropaenia 62 octreotide 62 safety tolerability pharmacokinetic 62 pharmacokinetic PK study 62 dasatinib 62 PEGylated interferon beta 1a 62 heavily pretreated 62 CR# vcMMAE 62 riociguat 62 pharmacodynamic effects 62 ALT flares 62 pomalidomide 62 Adverse events 62 ganetespib 62 Serious Adverse Events 62 interferon IFN 62 Teriflunomide 62 efficacy endpoint 62 R#/MEM # 62 hyperphenylalaninemia HPA due 62 Phase IIa trials 62 certolizumab 62 urocortin 2 62 tolerability 62 Hepatotoxicity 62 INC# 62 CIMZIA TM 62 ELND# 62 mg TID 62 TELCYTA 61 dose regimens 61 DAVANAT 61 decitabine 61 forodesine 61 CYT# potent vascular disrupting 61 huN# DM1 61 myelofibrosis polycythemia vera 61 TELINTRA 61 Pegasys ® 61 dose proportionality 61 GLYX 61 Phase Ib study 61 bone marrow suppression 61 lenalidomide dexamethasone 61 plasma kallikrein inhibitor 61 RSD# oral 61 neurotoxicity 61 tumor regression 61 S/GSK# 61 MYCAMINE 61 ara C 61 estramustine 61 PXD# 61 imatinib therapy 61 PROMACTA 61 mcg BID 61 neutropenia thrombocytopenia 61 BENICAR HCT 61 achieved statistical significance 61 teduglutide 61 OXi# 61 baminercept 61 dose escalation phase 61 cannabinor 61 transaminase elevations 61 mcg kg 61 Phase Ib 61 Phase 1b 61 pharmacokinetic characteristics 61 Valortim R 61 #mg/m# [002] 61 mg/m2/day 61 docetaxel Taxotere ® 61 elevated ALT 61 EDEMA3 61 IMGN# 61 GOUT 61 non nucleoside HCV 61 DermaVir Patch 61 samalizumab 61 mg BID 61 Hematologic toxicity 61 REYATAZ r arm 61 treatment emergent adverse 61 hepatotoxicity 61 pharmacodynamic profile 61 pharmacokinetic PK profile 61 virologic response 61 hypersensitivity reaction 61 ARIKACE 61 EXJADE 61 TG# [003] 61 Chemophase 61 Primary endpoints 61 CCX# 61 mg/m2 61 tumor regressions 61 tolerability profiles 61 R# #mg BID 61 intravesical 61 erythropoietic 61 remission CR 61 PREZISTA r arm 61 AEG# 61 rHuPH# 61 alicaforsen enema 61 placebo controlled clinical trials 61 dacetuzumab 61 biologic DMARD 61 Serious adverse reactions 61 evaluating tivozanib 61 FluCAM arm 60 polymerase inhibitor 60 CBLC# 60 hypersensitivity reactions 60 pyrexia mucositis sepsis febrile 60 VA# [002] 60 clinically meaningful improvement 60 Phase Ib clinical 60 tumor xenograft models 60 MNTX 60 liposomal formulation 60 severe neutropenia 60 tanespimycin 60 plasma uric acid 60 plasma concentrations 60 virologic failure 60 ACTEMRA TM 60 Phase Ib II 60 Actilon 60 mapatumumab 60 #D#C# 60 NATRECOR ® 60 tapentadol ER 60 recurrent glioblastoma multiforme 60 tolerability pharmacokinetics 60 interferon alfa 60 idarubicin 60 Phase 1a 60 refractory CLL 60 mg dose 60 aspartate aminotransferase 60 Pemetrexed 60 KNS # 60 AVE# 60 Sym# 60 intracranial hemorrhage ICH 60 mertansine 60 intermittent dosing 60 Adalimumab 60 partial remissions 60 Xanafide 60 complete remissions 60 blinded randomized placebo controlled 60 Symadex 60 Dasatinib 60 orally bioavailable 60 complete cytogenetic response 60 rapid virologic response 60 adalimumab 60 composite endpoint 60 demonstrated antitumor activity 60 bendamustine 60 AQ4N 60 active comparator 60 MAP# 60 HGS ETR2 60 splenectomized patients 60 inhibitor RG# 60 virological response 60 interferon alfa 2b 60 cytogenetic responses 60 pharmacokinetic parameters 60 safety tolerability pharmacokinetics 60 granisetron 60 velafermin belinostat 60 myopathy rhabdomyolysis 60 ritonavir boosted 60 antitumor effects 60 dyskinesia PD LID 60 Torsades de Pointes 60 docetaxel Taxotere R 60 dosed orally 60 octreotide LAR 60 4mg/kg 60 FOLPI regimen 60 PEGPH# 60 denileukin diftitox 60 tolvaptan 60 APOPTONE 60 orally dosed 60 LHRH antagonists 60 FOLFIRI 60 CTA# Injection 60 refractory AML 60 Eltrombopag 60 NGX# 60 Tolerability 60 mucocutaneous reactions 60 VAPRISOL 60 PRTX 60 alanine aminotransferase 60 Vidofludimus 60 ENMD # 60 systemic absorption 60 busulfan 60 antiviral activity 60 receiving INTRON 60 Triolex 60 eculizumab 60 MIRCERA 60 Enzastaurin 60 insulin degludec 60 μg dose 60 maximal tolerated 60 CEQ# 60 piperacillin tazobactam 60 myeloproliferative disorders 60 vitamin B# folic acid 60 azacitidine 60 Androxal TM 60 urate lowering 60 intravenous bisphosphonates 60 Azixa 60 leukemia AML 60 TORISEL 60 placebo controlled clinical 60 Dose escalation 60 certolizumab pegol 60 galiximab 60 viral kinetic 60 rindopepimut 60 Phase III Pivotal 60 KRN# 60 genotypic resistance 60 novel VDA molecule 60 #mg dose [002] 59 dosing schedules 59 Aztreonam lysine 59 serum phosphate 59 O PPDS 59 GRN#L 59 HBeAg positive patients 59 hypophosphatemia 59 alemtuzumab treated 59 tipranavir 59 #mg dose [001] 59 FOLFOX6 59 plus methotrexate 59 ZYVOX 59 papillary renal cell carcinoma 59 pharmacokinetics 59 aminotransferases 59 davunetide intranasal AL 59 tolerability profile 59 recurrent genital herpes 59 renal toxicity 59 dose escalation trial 59 AAG geldanamycin analog 59 endometrial hyperplasia 59 REVLIMID lenalidomide 59 pheochromocytoma 59 Hypersensitivity reactions 59 hematologic 59 aspartate aminotransferase AST 59 bevirimat Study 59 superficial bladder cancer 59 subcutaneous SC 59 APTIVUS 59 COPEGUS 59 bilirubin elevations 59 pan HDAC inhibitor 59 Darinaparsin 59 Febrile neutropenia 59 LEP ETU 59 solithromycin 59 ACTEMRA 59 dasatinib Sprycel ® 59 Ozarelix 59 sitaxsentan 59 LymphoStat B 59 Phase #/#a 59 latrepirdine 59 Omacetaxine mepesuccinate 59 lomitapide 59 brivaracetam 59 efalizumab 59 Archexin 59 orally administered inhibitor 59 SILENOR TM 59 rotigotine 59 timepoint 59 HMG CoA reductase inhibitors 59 taxane resistant 59 oblimersen 59 Cloretazine 59 selective modulator 59 Maximum Tolerated Dose MTD 59 nadolol 59 hour bronchodilation 59 metastatic RCC 59 EZN 59 flutamide 59 Thrombotic events 59 phase IIb study 59 relapsed SCLC 59 vismodegib 59 antiviral efficacy 59 ALB # 59 serum concentrations 59 cobiprostone 59 EGFR TKI 59 dapsone 59 Omacetaxine 59 BRIM2 59 ORMD 59 Randomized Double blind 59 TNFalpha 59 indibulin 59 cisplatin gemcitabine 59 CYT# 59 Durezol 59 PRADAXA 59 somatostatin analog 59 corticosteroid therapy 59 metaglidasen 59 IMC A# 59 6R BH4 59 blood Phe 59 investigational monoclonal antibody 59 Phase IIa trial 59 anaphylactoid reactions 59 CTAP# Capsules 59 sorafenib Nexavar 59 tocilizumab 59 ZOLINZA 59 overlapping toxicities 59 HGS# 59 histologies 59 mg/m2 cohort 59 varespladib 59 ELACYT 59 2 methoxyestradiol 59 recurrent glioma 59 KOMBIGLYZE XR 59 acute gout flares 59 imetelstat 59 elagolix 59 XL# XL# XL# 59 headache nasopharyngitis 59 EOquin 59 serum calcium 59 follicular lymphomas 59 definite stent thrombosis 59 dose escalation Phase 59 MGCD# [002] 59 serum phosphorus 59 Aurora kinase 59 budesonide foam 59 HGS ETR1 mapatumumab 59 Telintra 59 PS# [001] 59 OHR/AVR# 59 Prodarsan ® 59 SCH # 59 safety tolerability 59 abacavir lamivudine 59 vinca alkaloid 59 cidofovir 59 Darusentan 59 gemcitabine Gemzar ® 59 ALVESCO 59 PEGylated anti 59 mg BID dose 59 #I TM# 59 L PPDS 59 NP2 Enkephalin 59 pegylated liposomal doxorubicin 59 AEGR 59 LEXIVA r 59 ritonavir boosting 59 BARACLUDE ® 59 LY# [003] 59 efficacy endpoints 59 valopicitabine 59 Glufosfamide 59 serum calcium levels 59 PegIFN RBV 59 nalbuphine ER 59 OADs 59 mcg doses 59 pharmacokinetic equivalence 59 GRNVAC1 59 vandetanib 59 EOquin TM 59 Fibrillex TM 59 antitumour activity 59 Aclidinium 59 Pimavanserin 59 DOXIL 59 Methylnaltrexone 59 neratinib 59 receptor tyrosine kinase inhibitor 59 #mg BID [003] 59 YONDELIS 59 trastuzumab emtansine T DM1 59 pharmacodynamic parameters 59 phase IIb 59 Pralatrexate 59 immunomodulatory therapy 59 dose escalation study 59 adrenal suppression 59 viral kinetics 59 tipranavir r 59 Bortezomib 59 HCV genotypes 59 aflibercept VEGF Trap 59 lead Aganocide compound 59 relapsed MCL 59 MGd 59 CCyR 59 undetectable HBV DNA 58 chlorambucil 58 cell lymphoma CTCL 58 placebo controlled studies 58 arbaclofen 58 rFVIIa 58 Proellex TM 58 HCV protease 58 ketoconazole 58 mg QD 58 VELCADE melphalan 58 vWF 58 dose cytarabine 58 DDP# 58 transaminase 58 tumor necrosis 58 Kahalalide F 58 achieved ACR# 58 HQK 58 pharmacodynamics PD 58 trial evaluating PRX# 58 hypocalcemia 58 EGFR HER2 58 Revimmune 58 antiandrogen 58 HCV replicon 58 INT# [002] 58 Elotuzumab 58 tubulin inhibitor 58 inflammatory lesions 58 prospectively defined 58 clinically meaningful improvements 58 colorectal liver metastases 58 erlotinib Tarceva ® 58 Prodarsan 58 XL# XL# XL# XL# 58 ADAGIO study 58 XL# [003] 58 IIIa inhibitor 58 mg RDEA# 58 ibandronate 58 GFT# 58 Epratuzumab 58 intravenously administered 58 PD LID 58 infusion reactions 58 STRIDE PD 58 Thrombocytopenia 58 HBeAg positive 58 pharmacodynamic profiles 58 DEB# 58 insulin detemir 58 RhuDex ® 58 epithelial tumors 58 Asentar 58 hepatic dysfunction 58 mcg mL 58 transaminases 58 Tasimelteon 58 Pharmacokinetic parameters 58 RRMS patients 58 talactoferrin 58 phase IIb clinical 58 Infusion Reactions Severe 58 CDK inhibitor 58 mycophenolate mofetil 58 bortezomib 58 peginterferon 58 Zerenex 58 Myelosuppression 58 linear pharmacokinetics 58 PEG PAL 58 apremilast 58 xenograft tumors 58 TOLAMBA 58 Sapacitabine 58 AGILECT R 58 nonclinical studies 58 amprenavir 58 CIMZIA TM certolizumab pegol 58 radezolid 58 eosinophilic asthma 58 Phase 2b Clinical Trial 58 iobenguane 58 dacarbazine DTIC 58 PF # [001] 58 pulmonary exacerbations 58 REGN# 58 severe oral mucositis 58 fluticasone furoate 58 angiogenesis inhibitor 58 sufentanil 58 romidepsin 58 autoantibody positive 58 relapsed refractory multiple myeloma 58 catheter occlusion 58 pharmacodynamics 58 thrombocytopenia neutropenia 58 glufosfamide 58 leucopenia 58 PSN# [002] 58 tezampanel 58 sodium thiosulfate STS 58 Randomized Phase 58 Alocrest 58 AP# [003] 58 lintuzumab 58 Cloretazine R VNP#M 58 analgesic efficacy 58 oral ridaforolimus 58 refractory multiple myeloma 58 Afatinib 58 Phase #b/#a trial 58 TRIOLEX 58 AZILECT 58 serum phosphate levels 58 REMICADE ® 58 ertapenem 58 KAPIDEX 58 mg kg BID 58 ALISTA 58 ancrod 58 HuMax EGFr 58 TNF Tumor Necrosis Factor 58 elacytarabine 58 obatoclax 58 gout flares 58 bosentan 58 mg m² 58 INVEGA ® 58 serum phosphorous 58 HPA axis suppression 58 alfa 2a 58 multicenter randomized placebo controlled 58 bronchodilation 58 JAK inhibitor 58 treatment naive genotype 58 locoregional 58 ZD# [001] 58 HBeAg negative 58 steroid dexamethasone 58 abatacept 58 subcutaneously administered 58 Antiviral Activity 58 Solid Tumors 58 generalized seizures 58 apoptosis inducer 58 CD# CEA 58 MERLIN TIMI 58 cardiac repolarization 58 gemcitabine carboplatin 58 moderate renal impairment 58 goserelin 58 pharmacologically active isomer 58 liver transaminases 58 AST ALT 58 fosamprenavir 58 MEK inhibitor 58 prasterone 58 Apoptone 58 pancytopenia 58 highly immunogenic 58 PRE SURGE 58 multicenter Phase III 58 dose titration 58 squalamine 58 palonosetron 58 placebo controlled Phase 58 Tyrima 58 GW# [003] 58 isatoribine 58 venlafaxine XR 58 Triapine R 58 nucleoside naive patients 58 pCR 58 fondaparinux 58 fluvastatin 58 gemcitabine cisplatin 58 bevacizumab Avastin ® 58 Phenoptin 58 dose proportional pharmacokinetics 58 tiotropium bromide 58 Amplimexon 58 NLX P# 58 vidofludimus 58 placebo controlled trials 58 EDEMA4 trial 58 interferon gamma 1b 58 favorable tolerability 58 immunological responses 58 amrubicin 58 Microplasmin 58 pegloticase 58 doxorubicin cyclophosphamide 58 daunorubicin 58 protease inhibitor PI 58 Phase 1b trial 58 JANUVIA 58 Tindamax R 58 motesanib 58 mitoxantrone 58 clinically meaningful reductions 58 hA# 58 antipsychotic efficacy 58 Voreloxin 58 Forodesine HCl 58 Hepatocellular Carcinoma HCC 58 Gemzar ® 58 RGB # 58 CORT # 58 Exelixis compounds 58 seropositive patients 58 diabetic neuropathic pain 58 metastatic neuroendocrine tumors 58 vicriviroc 58 Hypotension 58 tumor shrinkage 58 monotherapy 58 Dapagliflozin 58 clinically meaningful 58 Cutaneous T 58 noninferiority 58 CLORETAZINE TM VNP#M 58 HCV SPRINT 58 histone deacetylase HDAC inhibitor 58 Ostarine 58 Parkinson disease levodopa induced 57 novel histone deacetylase 57 neutropenia 57 antibody titers 57 Pharmacokinetic 57 TRAIL R1 57 EXPAREL TM 57 OncoVEX GM CSF 57 FFNS 57 xenograft models 57 synthetic retinoid 57 SAR# [004] 57 active moiety 57 highly emetogenic 57 dacarbazine 57 Aflibercept 57 Entereg R 57 Phase 2b Trial 57 Aurexis 57 mcg dose 57 mg/m2 administered 57 AEs 57 ziconotide 57 optimal dosing 57 Multimeric 57 PEG IFN 57 trastuzumab Herceptin R 57 hepatic impairment 57 HIF PHI 57 BAL# [002] 57 OvaRex ® MAb 57 albiglutide 57 NRTI resistance 57 Elagolix 57 Plicera 57 anemia neutropenia 57 pharmacokinetic 57 cytotoxicity 57 systemic corticosteroid 57 metastatic GIST 57 acute GvHD 57 mg/# h 57 HER2 positive metastatic breast 57 bicifadine 57 caspofungin 57 lanreotide 57 nucleotide analog 57 subcutaneous dose 57 IDX# 57 trabedersen 57 opioid induced bowel dysfunction 57 XP# Transported Prodrug 57 QTc 57 Peg IFN 57 postoperative chemotherapy 57 pyrazinamide 57 Dacogen injection 57 relapsed AML 57 EDEMA3 trial 57 MGCD# [001] 57 GEMZAR 57 montelukast 57 AZT zidovudine Retrovir 57 pericardial effusion 57 Angioedema 57 macrolide antibiotic 57 nucleoside reverse transcriptase inhibitor 57 telaprevir dosed 57 MULTAQ 57 QTc interval 57 continuous intravenous infusion 57 uric acid lowering 57 TLK# 57 QT prolongation 57 alanine aminotransferase ALT 57 TTF Therapy 57 interferon beta therapy 57 hemagglutination inhibition HAI 57 stage IIIB 57 ISIS # 57 pharmacokinetics pharmacodynamics 57 GnRH agonist 57 oral methylnaltrexone 57 zileuton 57 darunavir ritonavir 57 microgram kg 57 SinuNase TM 57 Zoraxel 57 remission induction 57 corticosteroid dose 57 sulfasalazine 57 bevirimat 57 proteinuria 57 ATL/TV# 57 HIV RNA 57 serum HBV DNA 57 hyperbilirubinemia 57 ozarelix 57 Golimumab 57 non nucleoside 57 HBeAg seroconversion 57 ZYBRESTAT fosbretabulin 57 EVIZON 57 iniparib 57 MEND CABG II 57 Cmax 57 Tumor shrinkage 57 JVRS 57 alvimopan 57 antiangiogenic activity 57 alpha interferons 57 Meets Primary Endpoint 57 tecarfarin 57 adriamycin 57 imatinib resistant 57 Phase 1b clinical 57 NRTIs 57 primary hypercholesterolemia 57 Virulizin ® 57 Pharmacokinetic studies 57 peg IFN 57 cytotoxic chemotherapy 57 lopinavir r arm 57 mGluR5 negative 57 antitumor effect 57 oral FTY# 57 nonhematologic adverse reactions 57 non splenectomized 57 randomized discontinuation trial 57 visilizumab 57 Altastaph 57 preclinical efficacy 57 FOSRENOL ® 57 HIV HCV coinfected 57 label dose escalation 57 ribavirin therapy 57 gastrointestinal toxicity 57 eosinophilia 57 farletuzumab 57 QD dosing 57 temsirolimus 57 androgen independent 57 ACAPODENE 57 Non inferiority 57 uricase 57 SCIg 57 Arikace 57 saline placebo 57 NATRECOR R 57 febuxostat 57 pharmacodynamic markers 57 mg administered orally 57 IIa trial 57 Phase IIa clinical 57 Phase 1a clinical 57 LB# [003] 57 thrombocytopenic 57 mTOR inhibitors 57 PASI scores 57 melphalan prednisone 57 Trastuzumab 57 mucosal healing 57 TYSABRI treated 57 blood phenylalanine Phe 57 Cariprazine 57 thorough QT 57 ARCALYST ® 57 SVR# 57 nilotinib 57 subcutaneous doses 57 eltrombopag 57 adalimumab Humira 57 standard chemotherapy regimen 57 ularitide 57 MGUS 57 Tolvaptan 57 nelfinavir 57 calcineurin inhibitors 57 acute HAE attacks 57 ribavirin RBV 57 nitazoxanide 57 aminotransferase levels 57 prostanoid 57 leucovorin 57 Multiple Ascending Dose 57 DaTscan 57 depsipeptide 57 pulmonary hypertension PH 57 peritumoral brain edema 57 Phase #b/#a 57 primidone 57 metastatic castration resistant 57 mitomycin 57 degarelix 57 Vacc 4x 57 torsade de pointes 57 Phase IIB 57 pulmonary toxicity 57 mesalamine granules 57 PEGINTRON TM 57 vinorelbine 57 metastatic malignant 57 essential thrombocythemia 57 prucalopride 57 TRO# 57 omega interferon 57 Vidaza azacitidine 57 multicenter Phase II 57 cerebrovascular events 57 mucositis 57 Phase Ib clinical trials 57 histologically confirmed 57 aflibercept 57 COZAAR 57 platinum refractory 57 ALN TTR 57 Phase 2a clinical trials 57 zonisamide SR 57 alagebrium 57 belinostat 57 paricalcitol 57 ZACTIMA 57 Hsp# Inhibitor 57 castration resistant prostate cancer 57 aminotransferase ALT 57 oxycodone CR 57 thalidomide Thalomid 57 irbesartan